JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldberg, L. I.
Right arrow Articles by Sjoerdsma, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldberg, L. I.
Right arrow Articles by Sjoerdsma, A.
Journal of Pharmacology And Experimental Therapeutics, Vol. 127, Issue 3, 212-218, 1959
Copyright © 1959 by American Society for Pharmacology and Experimental Therapeutics

EFFECTS OF SEVERAL MONOAMINE OXIDASE INHIBITORS ON THE CARDIOVASCULAR ACTIONS OF NATURALLY OCCURRING AMINES IN THE DOG

Leon I. Goldberg 1 and Albert Sjoerdsma 1

1 Section on Experimental Therapeutics, National Heart Institute, National Institutes of Health, Bethesda, Maryland

The effects of six monoamine oxidase (MAO) inhibitors (JB-516, JB-835, RO-50700, harmine, harmaline and iproniazid) on the cardiovascular actions of norepinephrine, dopamine, tryptamine, tyramine and serotonin were studied in the anesthetized dog.

The actions of dopamine, tryptamine and tyramine on heart contractile force and arterial pressure were significantly augmented by all inhibitors. It is postulated that this potentiation is related to MAO inhibition.

The actions of norepinephrine were not significantly altered by the administration of the inhibitors. The effects of serotonin were decreased by all inhibitors except RO-50700.

The acute cardiovascular actions of the various inhibitors differed considerably and were apparently unrelated to the MAO-blocking property of the drugs.

Submitted on May 15, 1959




This article has been cited by other articles:


Home page
 NEJMHome page
M. B. Murphy, C. Murray, and G. D. Shorten
Fenoldopam -- A Selective Peripheral Dopamine-Receptor Agonist for the Treatment of Severe Hypertension
N. Engl. J. Med., November 22, 2001; 345(21): 1548 - 1557.
[Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1959 by the American Society for Pharmacology and Experimental Therapeutics.